Nicotinamide mononucleotide

WORCESTER, Mass.--(BUSINESS WIRE)--Metro International Biotech, LLC (MetroBiotech), an EdenRoc Sciences company that is developing more effective treatments of age-related diseases, today announced that the first patients in Cohort 1 of its Phase 1a clinical trial of MIB-725 have received their initial doses. MIB-725 is a new, proprietary investigational drug that has been demonstrated in preclinical studies to be a potent NAD precursor or booster. MIB-725 is a new, proprietary investigational drug that has been demonstrated in preclinical studies to be a potent NAD precursor or booster. In this Phase 1a single ascending dose study, the safety, pharmacokinetics, metabolism and effect of MIB-725 on circulating NAD levels will be determined. Later trials will investigate MIB-725’s efficacy in treating chronic kidney disease associated with aging. In the initial four of eight patients to be dosed in the first cohort, no dose-limiting toxicities were observed. Once the remaining patients are dosed in the cohort, subsequent doses will be gradually increased. If this single dose trial is concluded successfully, a follow-on trial with multiple dosing (Phase 1b) will be run at the same site by the investigators. "Commencement of Phase 1 testing of our novel NAD booster is a key step in our vision of developing the potential of a family of NAD precursor compounds optimized for particular therapeutic indications,” said David Livingston, Ph.D., president and chief scientific officer of MetroBiotech. “The current single ascending dose trial of MIB-725 will create our first safety, PK/PD and metabolic database for this unique molecule, and is an important milestone in our company’s clinical development program. We believe this trial will inform the compound expansion stage of our ongoing clinical trials and may allow us to obtain initial evidence of clinical activity as the program continues to advance." About MIB-725 MIB-725 is the second MetroBiotech therapeutic candidate that targets diseases of aging such as kidney disease, neurodegenerative disease, and muscle disorders. A robust Phase 2 clinical program is ongoing for MetroBiotech’s initial investigational drug MIB-626. Both MIB-626 and MIB-725 have shown pharmacological activity in a variety of preclinical models that demonstrated NAD boosting effects, as well as suppression of pancreatitis, acute kidney injury, and rare mitochondrial disease-associated cardiovascular function. These two compounds are differentially used in NAD-elevating pathways in mammals. About Metro International Biotech, LLC MetroBiotech, an EdenRoc Sciences company, is a clinical-stage metabolism company focused on treating diseases of aging such a muscle weakness, kidney diseases, neurodegenerative diseases, and cancer. MetroBiotech is committed to treating such diseases with NAD boosters of high safety that can effectively target different organs. Through intelligent medicinal chemistry design and process development, the company is producing pharmaceutical-grade NAD boosters at the scale required for early- and late-stage clinical testing. The ongoing independent Phase 1 clinical trials of MIB-725, as well as the Phase 2 clinical trials of MIB-626, are all being run under INDs cleared by FDA. MetroBiotech’s commitment to FDA standards for investigational drugs make the company unique in the NAD booster space. Learn more at metrobiotech.com. Forward-Looking Statements This release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including, without limitation, statements concerning the timing, conduct and results of the Phase 1 clinical trial, statements about microRNAs and their involvement in cancer, and statements concerning the therapeutic potential of MetroBiotech's MIB-725. Any forward-looking statements in this press release are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to: the risks associated with drug discovery and development; the risk that the results of clinical trials will not be consistent with MetroBiotech's pre-clinical studies or expectations or with results from previous clinical trials; risks associated with the conduct of clinical trials; risks associated with MetroBiotech's financial condition and its need to obtain additional funding to support its business activities, including MetroBiotech's ability to continue as a going concern; risks associated with the timing and outcome of MetroBiotech's planned regulatory submissions; risks associated with obtaining, maintaining and protecting intellectual property; risks associated with MetroBiotech's ability to enforce its patents against infringers and defend its patent portfolio against challenges from third parties; risks of competition from other companies developing products for similar uses; risks associated with MetroBiotech's dependence on third parties; and risks associated with geopolitical events and pandemics, including the COVID-19 coronavirus and military actions. All information in this press release is as of the date of this release; MetroBiotech undertakes no duty to update this information unless required by law. For more information, please contact: Metro International Biotech’s President & CSO David J. Livingston, Ph.D., MBA at info@metrobiotech.com. More information is available at the company’s website: www.metrobiotech.com © METRO INTERNATIONAL BIOTECH, LLC. ALL RIGHTS RESERVED.

TOKYO--(BUSINESS WIRE)--Mirailab Bioscience Inc. (Head office: Chuo-ku, Tokyo, CEO: Megumi Tanaka) has obtained patent rights in China for "Food or beverage for babies and infants, method for improving intestinal environment of baby or infant, and method for enhancing immunity of baby or infant" which had been pending a patent (PCT) international application. Patent Summary Application No. : PCT/JP2020/004947 (Chinese Patent 113438896) Name of invention (in English): Food or beverage for babies and infants, method for improving intestinal environment of baby or infant, and method for enhancing immunity of baby or infant It is a patent for a method for improving the immature intestinal environment of baby or infant and a method for enhancing immunity of baby or infant, and is characterized by the inclusion of nicotinamide mononucleotide (NMN) in food or beverage for babies and infants. Compared to infants raised on breast milk, infants raised on conventional milk powder tend to be more susceptible to infectious diseases due to insufficient immunity or disorder of the intestinal environment caused by the imbalance between bifidobacteria, which are beneficial bacteria, and E. coli, which are harmful bacteria in the intestinal flora, so the development of infant foods and beverages that have enhanced intestinal environment improvement and immunostimulatory capacity (infection defense function) has been awaited. Therefore, the present invention develops an infant food and beverage containing NMN, and provides an infant food and beverage that can improve the intestinal environment of infants and strengthen their immunity, a method for improving the intestinal environment of infants and a method for enhancing immunity of infants. In addition, the present invention is expected to be effective in babies and infants who mainly consume infant milk powder, infants whose intestinal environment has disordered, and infants with low immunity. About NMN NMN is a component that is naturally produced in the body using materials such as vitamin B3, and is an indispensable substance for the activity of cells in the body. It is also believed that the decrease in NMN production in the body with age is one of the factors that exacerbates various age-related diseases (lifestyle-related diseases, cancer, dementia, etc.). In recent years, there has been an acceleration in the application of the excellent properties of NMN, such as anti-aging, treatment of neurodegenerative diseases, and protection of the heart, to functional food ingredients, healthcare products, pharmaceuticals and pharmaceutical intermediates. Examples Evaluation of the effect of promoting immunoglobulin M (IgM) production In order to confirm the change in IgM concentration in the blood due to the intake of infant food and drink containing nicotinamide mononucleotide, a test was conducted on male and female infants aged 1.8~6.5 years. IgM is a type of antibody that is first produced from immune cells called B cells when infected with bacteria or viruses. 23 infants were divided into two groups, one group (11 infants) was fed powdered milk alone, and the other group (12 infants) was fed powdered milk with nicotinamide mononucleotide (compound (+)) once a day in the morning for approximately 30 days, and the IgM concentration (mg/dl) in the blood in each group was measured before lactation and after about 30 days of feeding. The average value was determined (except for subjects with IgM concentrations less than 120 mg/dl in their blood before breastfeeding). The group that was fed powdered milk supplemented with nicotinamide mononucleotide was fed powdered milk containing 100 mg of nicotinamide mononucleotide per day. As shown in the figure, the IgM concentration had a greater increase from before to after breastfeeding in the group that was fed powdered milk supplemented with nicotinamide mononucleotide compared to the group that was fed powdered milk alone. From these results, it was found that the infant food and drink of the present invention is effective in increasing the IgM concentration in the blood. About Mirailab Bioscience Inc. We are a leading company for NMN that starts selling NMN supplements in 2015, first in the world (1). With the aim of realizing scientifically based "productive aging" all over the world, we will continue to contribute to the improvement of quality of life through the expansion of the mail-order series for analysis of health levels that enables quantification of the effects of NMN, "MiRMes" Mirailab Remote Medical Check Series (2) and the supply of NMN supplements, NMN infusion research reagent raw materials, NMN-containing cosmetics, etc. (3). (1) https://www.atpress.ne.jp/news/59540 (2) https://prtimes.jp/main/html/rd/p/000000015.000103030.html (3) https://mirai-lab.jpn.com/pages/history